GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcellx Inc (NAS:ACLX) » Definitions » PS Ratio

Arcellx (Arcellx) PS Ratio : 23.11 (As of May. 04, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Arcellx PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Arcellx's share price is $52.69. Arcellx's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.28. Hence, Arcellx's PS Ratio for today is 23.11.

Good Sign:

Arcellx Inc stock PS Ratio (=23.18) is close to 2-year low of 22.65

The historical rank and industry rank for Arcellx's PS Ratio or its related term are showing as below:

ACLX' s PS Ratio Range Over the Past 10 Years
Min: 22.42   Med: 49.28   Max: 113.79
Current: 22.52

During the past 5 years, Arcellx's highest PS Ratio was 113.79. The lowest was 22.42. And the median was 49.28.

ACLX's PS Ratio is ranked worse than
68.2% of 997 companies
in the Biotechnology industry
Industry Median: 9.03 vs ACLX: 22.52

Arcellx's Revenue per Sharefor the three months ended in Dec. 2023 was $1.29. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.28.

Back to Basics: PS Ratio


Arcellx PS Ratio Historical Data

The historical data trend for Arcellx's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcellx PS Ratio Chart

Arcellx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - - 24.18

Arcellx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 80.44 46.50 36.28 24.18

Competitive Comparison of Arcellx's PS Ratio

For the Biotechnology subindustry, Arcellx's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcellx's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcellx's PS Ratio distribution charts can be found below:

* The bar in red indicates where Arcellx's PS Ratio falls into.



Arcellx PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Arcellx's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=52.69/2.28
=23.11

Arcellx's Share Price of today is $52.69.
Arcellx's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.28.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Arcellx  (NAS:ACLX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Arcellx PS Ratio Related Terms

Thank you for viewing the detailed overview of Arcellx's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcellx (Arcellx) Business Description

Traded in Other Exchanges
N/A
Address
25 West Watkins Mill Road, Suite A, Gaithersburg, MD, USA, 20878
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
Executives
Michelle Gilson officer: Chief Financial Officer 25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG MD 20878
Christopher Heery officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Rami Elghandour director, officer: See Remarks 15 BARCELONA CIR, REDWOOD CITY CA 94065
Jill Carroll director C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Sr One Capital Management, Llc 10 percent owner 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Sr One Co-invest Ii Manager, Llc 10 percent owner 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093